These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21957946)

  • 1. Valuing mortality risk reductions from environmental, transport, and health policies: a global meta-analysis of stated preference studies.
    Lindhjem H; Navrud S; Braathen NA; Biausque V
    Risk Anal; 2011 Sep; 31(9):1381-407. PubMed ID: 21957946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of a statistical life in road safety: a benefit-transfer function with risk-analysis guidance based on developing country data.
    Milligan C; Kopp A; Dahdah S; Montufar J
    Accid Anal Prev; 2014 Oct; 71():236-47. PubMed ID: 24952315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of a statistical life in Sweden: a review of the empirical literature.
    Hultkrantz L; Svensson M
    Health Policy; 2012 Dec; 108(2-3):302-10. PubMed ID: 23084655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of real options on willingness to pay for mortality risk reductions.
    Krüger NA; Svensson M
    J Health Econ; 2009 May; 28(3):563-9. PubMed ID: 19261344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is a life worth? Robustness of VSL values from contingent valuation surveys.
    Alberini A
    Risk Anal; 2005 Aug; 25(4):783-800. PubMed ID: 16268929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Willingness to pay for private and public road safety in stated preference studies: why the difference?
    Svensson M; Vredin Johansson M
    Accid Anal Prev; 2010 Jul; 42(4):1205-12. PubMed ID: 20441833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminishing willingness to pay per quality-adjusted life year: valuing acute foodborne illness.
    Haninger K; Hammitt JK
    Risk Anal; 2011 Sep; 31(9):1363-80. PubMed ID: 21488924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP?
    Van Houtven G; Powers J; Jessup A; Yang JC
    Health Econ; 2006 Aug; 15(8):775-95. PubMed ID: 16544361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuing life: a plea for disaggregation.
    Sunstein CR
    Duke Law J; 2004 Nov; 54(2):385-445. PubMed ID: 15940845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research Synthesis and the Value per Statistical Life.
    Robinson LA; Hammitt JK
    Risk Anal; 2015 Jun; 35(6):1086-100. PubMed ID: 25851065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contingent Valuation: A Pilot Study for Eliciting Willingness to Pay for a Reduction in Mortality From Vaccine-Preventable Illnesses for Children and Adults in Bangladesh.
    Odihi D; De Broucker G; Hasan Z; Ahmed S; Constenla D; Uddin J; Patenaude B
    Value Health Reg Issues; 2021 May; 24():67-76. PubMed ID: 33508753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Publication selection and the income elasticity of the value of a statistical life.
    Doucouliagos H; Stanley TD; Viscusi WK
    J Health Econ; 2014 Jan; 33():67-75. PubMed ID: 24300998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis.
    Robinson LA; Hammitt JK; O'Keeffe L
    J Benefit Cost Anal; 2019; 10(Suppl 1):15-50. PubMed ID: 32968616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valuing non-marginal changes in mortality and morbidity risk.
    Herrera-Araujo D; Rheinberger CM; Hammitt JK
    J Health Econ; 2022 Jul; 84():102627. PubMed ID: 35569207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Willingness to pay for road safety and estimates of the risk of death: evidence from a Swedish contingent valuation study.
    Andersson H
    Accid Anal Prev; 2007 Jul; 39(4):853-65. PubMed ID: 17292319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits transfer of willingness to pay estimates and functions for health-risk reductions: a cross-country study.
    Brouwer R; Bateman IJ
    J Health Econ; 2005 May; 24(3):591-611. PubMed ID: 15811545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of risk representation and scope on willingness to pay for reduced risks: evidence from Tokyo Bay, Japan.
    Zhai G; Suzuki T
    Risk Anal; 2008 Apr; 28(2):513-22. PubMed ID: 18419666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the Benefits of COVID-19 Policies Exceed the Costs? Exploring Uncertainties in the Age-VSL Relationship.
    Robinson LA; Sullivan R; Shogren JF
    Risk Anal; 2021 May; 41(5):761-770. PubMed ID: 32677076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefits of avoiding cancer (or dying from cancer): Evidence from a four- country study.
    Alberini A; Ščasný M
    J Health Econ; 2018 Jan; 57():249-262. PubMed ID: 28864334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.